If you open your company benefits packet this fall and find that Wegovy or Zepbound has vanished, you aren't imagining things. Across the corporate landscape, major U.S. employers are actively scaling back or entirely stripping glucagon-like peptide-1 medications from their health plan formularies for 2027.
Surveys from organizations like the Business Group on Health and WTW show that roughly 14 percent of large employers have dropped or plan to drop GLP-1 weight-management coverage heading into next year. The share of large companies covering these drugs for obesity management has slid from around 72 percent down to roughly 60 percent.
Companies are slamming the brakes on coverage not because the science has failed. They are backing away because the math no longer balances.
The Core Problem Driving the 2027 Cutbacks
At the center of this benefit contraction lies raw financial pressure. Brand-name anti-obesity medications typically run in the mid-$500s to mid-$600s per user monthly through standard pharmacy benefit channels. When thousands of employees clamor for a lifetime prescription, corporate healthcare premiums spike.
According to benefits consultants at Marsh, average health insurance costs per employee are projected to climb sharply, with GLP-1 utilization driving a noticeable chunk of that increase. Human resources departments find themselves caught between wanting to support workforce wellness and facing budgets that cannot absorb open-ended, multi-thousand-dollar annual costs per patient.
Some major employers have opted for a middle path. They continue covering GLP-1s for type 2 diabetes, cardiovascular indications, or sleep apnea while carving out pure weight-loss prescriptions. Others are exploring new approaches, such as health reimbursement accounts or direct-to-consumer pharmacy arrangements, to shift away from traditional plan liabilities.
What This Means for Your Open Enrollment Decisions
Finding your medication missing from the 2027 formulary requires immediate action rather than passive frustration. Benefits administrators structure these changes tightly around annual renewals, leaving little room for mid-year exceptions once the plan year locks.
Start by digging into your Summary of Benefits and Coverage. Check whether the drug is entirely missing, shifted to a prohibitive specialty tier, or now demands strict prior authorization. You need to know if your plan requires a specific body mass index threshold, a documented comorbidity, or mandatory enrollment in a lifestyle program.
Talk to your prescribing physician long before January arrives. If your employer has shut the door on weight-loss indications, your doctor can evaluate whether your medical history meets criteria for an alternative diagnosis like obstructive sleep apnea or cardiovascular risk reduction. Under these clinical umbrellas, insurance coverage sometimes remains intact.
Alternative Paths If Your Insurance Says No
Losing employer sponsorship doesn't automatically mean stopping treatment cold turkey, but it does mean navigating a more expensive landscape.
Direct-to-consumer manufacturer channels have expanded rapidly. Companies like Eli Lilly and Novo Nordisk have built direct purchasing platforms offering vial and pen options at reduced list prices compared to traditional pharmacy markups. While these out-of-pocket costs still require serious budgeting, they bypass traditional insurance roadblocks entirely.
Flexible spending accounts and health savings accounts offer another layer of relief. Because self-pay GLP-1 expenses generally qualify as eligible medical costs, you can maximize your pre-tax contributions during open enrollment to blunt the financial sting.
Corporate health benefits are shifting toward strict cost containment. Protecting your health outcomes in 2027 means auditing your plan documents today, partnering with your physician to explore clinical exceptions, and mapping out a realistic financial plan before your old coverage expires.
